Competitive blocking of salivary gland [18F]DCFPyL uptake via localized, retrograde ductal injection of non-radioactive DCFPyL: a preclinical study
暂无分享,去创建一个
P. Choyke | J. Chiorini | C. Zheng | R. Pieschl | J. Roy | B. Warner | F. Lin | R. Swenson | F. Basuli | Karen J. Wong | Xiang-qian Zhang | Tim E. Phelps | A. Ton | Corrine Goldsmith | Margaret E. White | Xiang Zhang | Jyoti Roy | Anita T. Ton | Frank I. Lin
[1] M. Stockler,et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial , 2021, The Lancet.
[2] D. Elashoff,et al. The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study , 2021, The Journal of Nuclear Medicine.
[3] S. Larson,et al. A simple strategy to reduce the salivary gland and kidney uptake of PSMA targeting small molecule radiopharmaceuticals , 2020, bioRxiv.
[4] P. Choyke,et al. Comparison of Prostate-Specific Membrane Antigen Expression Levels in Human Salivary Glands to Non-Human Primates and Rodents. , 2020, Cancer biotherapy & radiopharmaceuticals.
[5] F. Bruchertseifer,et al. Correction to: 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[6] R. Baum,et al. Salivary gland toxicity after PRLT using Lu-177 PSMA in patients with advanced prostate cancer: A single-center systematic investigation , 2019 .
[7] P. Meyer,et al. [177Lu]Lu-PSMA-617 Salivary Gland Uptake Characterized by Quantitative In Vitro Autoradiography , 2019, Pharmaceuticals.
[8] U. Haberkorn,et al. Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[9] W. Cai,et al. Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine. , 2018, American journal of nuclear medicine and molecular imaging.
[10] F. Bénard,et al. Monosodium Glutamate Reduces 68Ga-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model , 2018, The Journal of Nuclear Medicine.
[11] R. Baum,et al. Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies , 2018, The Journal of Nuclear Medicine.
[12] Hossein Jadvar,et al. PSMA Theranostics: Current Status and Future Directions , 2018, Molecular imaging.
[13] D. Murphy,et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. , 2018, The Lancet. Oncology.
[14] U. Haberkorn,et al. PSMA-Targeted Radionuclide Therapy and Salivary Gland Toxicity: Why Does It Matter? , 2018, The Journal of Nuclear Medicine.
[15] R. Baum,et al. Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept , 2018, Nuclear Medicine and Molecular Imaging.
[16] T. Teshima,et al. Overview of Human Salivary Glands: Highlights of Morphology and Developing Processes , 2017, Anatomical record.
[17] D. Cohen,et al. Publisher's Note , 2017, Neuroscience & Biobehavioral Reviews.
[18] P. Choyke,et al. Fast indirect fluorine-18 labeling of protein/peptide using the useful 6-fluoronicotinic acid-2,3,5,6-tetrafluorophenyl prosthetic group: A method comparable to direct fluorination. , 2017, Journal of labelled compounds & radiopharmaceuticals.
[19] W. Brenner,et al. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients , 2017, Journal of Nuclear Medicine.
[20] K. Strauch,et al. Safety and Efficacy of Botulinum Toxin to Preserve Gland Function after Radiotherapy in Patients with Head and Neck Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blinded Phase I Clinical Trial , 2016, PloS one.
[21] S. F. Konieczny,et al. Salivary gland homeostasis is maintained through acinar cell self-duplication. , 2015, Developmental cell.
[22] M. Trombetta,et al. Ultrasound-assisted non-viral gene transfer of AQP1 to the irradiated minipig parotid gland restores fluid secretion , 2015, Gene Therapy.
[23] A. Villa,et al. Diagnosis and management of xerostomia and hyposalivation , 2014, Therapeutics and clinical risk management.
[24] C. Hemmelmann,et al. Radioprotective effect of lidocaine on function and ultrastructure of salivary glands receiving fractionated radiation. , 2012, International journal of radiation oncology, biology, physics.
[25] M. Pomper,et al. 2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer , 2011, Clinical Cancer Research.
[26] A. Vissink,et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life , 2010, Supportive Care in Cancer.
[27] O. Grundmann,et al. Sensitivity of Salivary Glands to Radiation: from Animal Models to Therapies , 2009, Journal of dental research.
[28] S. Landas,et al. Expression of Prostate-Specific Membrane Antigen in Normal and Malignant Human Tissues , 2006, World Journal of Surgery.
[29] W. Tong,et al. Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase , 2001, Mammalian Genome.
[30] D. Bostwick,et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. , 1998, Urology.
[31] B. Baum,et al. Immediate inflammatory responses to adenovirus-mediated gene transfer in rat salivary glands. , 1996, Human gene therapy.